Related Experiment Videos
Anti-TNF-alpha therapies: the next generation
Michael A Palladino1, Frances Rena Bahjat, Emmanuel A Theodorakis
1Nereus Pharmaceuticals, 10480 Wateridge Circle, San Diego, California 92121, USA. mpalladino@nereuspharm.com
Nature Reviews. Drug Discovery
|September 3, 2003
Summary
New oral small molecules offer a promising alternative to injectable therapies for regulating tumor necrosis factor-alpha (TNF-alpha). These could improve treatment for inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease.
Area of Science:
- Immunology and Inflammation
- Pharmacology and Drug Discovery
Background:
- Immune system balance relies on pro-inflammatory and anti-inflammatory cytokines.
- Dysregulated cytokine activity, particularly tumor necrosis factor-alpha (TNF-alpha), drives inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease.
Purpose of the Study:
- To review current understanding of TNF-alpha biology and existing therapies.
- To explore novel therapeutic strategies involving oral, small-molecule inhibitors of TNF-alpha.
Main Methods:
- Review of existing literature on TNF-alpha pathways and therapeutic interventions.
- Focus on the development and potential of small-molecule oral inhibitors.
Main Results:
- Current injectable biologic therapies targeting TNF-alpha have shown success but possess risks and limitations.
- Oral small-molecule inhibitors represent a potential advancement in TNF-alpha regulation.
Conclusions:
- Oral small molecules could offer a safer and more convenient alternative to injectable TNF-alpha inhibitors.
- These novel agents may enhance disease control as monotherapy or in combination with existing treatments for inflammatory conditions.